DK3334431T3 - 5-brom-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amin til anvendelse til behandling af cancer - Google Patents

5-brom-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amin til anvendelse til behandling af cancer Download PDF

Info

Publication number
DK3334431T3
DK3334431T3 DK16766384.8T DK16766384T DK3334431T3 DK 3334431 T3 DK3334431 T3 DK 3334431T3 DK 16766384 T DK16766384 T DK 16766384T DK 3334431 T3 DK3334431 T3 DK 3334431T3
Authority
DK
Denmark
Prior art keywords
pyrazol
pyrimidin
bromo
amine
cancer treatment
Prior art date
Application number
DK16766384.8T
Other languages
English (en)
Inventor
Sanela Bilic
Gomez Juan Alberto Camacho
John Scott Cameron
Laria Julio Cesar Castro-Palomino
Jr Danny Roland Howard
Original Assignee
Novartis Ag
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Palobiofarma Sl filed Critical Novartis Ag
Priority claimed from PCT/IB2016/054834 external-priority patent/WO2017025918A1/en
Application granted granted Critical
Publication of DK3334431T3 publication Critical patent/DK3334431T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK16766384.8T 2015-08-11 2016-08-10 5-brom-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amin til anvendelse til behandling af cancer DK3334431T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382425 2015-08-11
US201662335984P 2016-05-13 2016-05-13
PCT/IB2016/054834 WO2017025918A1 (en) 2015-08-11 2016-08-10 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
DK3334431T3 true DK3334431T3 (da) 2020-01-02

Family

ID=65563017

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16766384.8T DK3334431T3 (da) 2015-08-11 2016-08-10 5-brom-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amin til anvendelse til behandling af cancer

Country Status (13)

Country Link
JP (1) JP6964113B2 (da)
KR (1) KR102226100B1 (da)
CL (1) CL2018000349A1 (da)
DK (1) DK3334431T3 (da)
ES (1) ES2761910T3 (da)
HK (1) HK1249409B (da)
HR (1) HRP20192192T1 (da)
HU (1) HUE046646T2 (da)
IL (1) IL257350A (da)
LT (1) LT3334431T (da)
PT (1) PT3334431T (da)
RU (1) RU2745560C2 (da)
ZA (1) ZA201800792B (da)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.

Also Published As

Publication number Publication date
HUE046646T2 (hu) 2020-03-30
RU2018108050A (ru) 2019-09-13
JP2019218346A (ja) 2019-12-26
ZA201800792B (en) 2019-06-26
JP6964113B2 (ja) 2021-11-10
RU2745560C2 (ru) 2021-03-29
HRP20192192T1 (hr) 2020-03-06
HK1249409B (zh) 2020-05-08
KR102226100B1 (ko) 2021-03-10
IL257350A (en) 2018-03-29
LT3334431T (lt) 2019-12-27
KR20200057790A (ko) 2020-05-26
ES2761910T3 (es) 2020-05-21
RU2018108050A3 (da) 2020-02-17
CL2018000349A1 (es) 2018-09-07
PT3334431T (pt) 2020-01-06

Similar Documents

Publication Publication Date Title
DK3580211T3 (da) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
RS59688B1 (sr) 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3468965T3 (da) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer
DK3582853T3 (da) Cykliske dinukleotidforbindelser til behandling af cancer
DK3445850T3 (da) Fremgangsmåder til tilvejebringelse af enkeltstrenget rna
DK3365373T3 (da) Bindingsmolekyler, der hæmmer cancervækst
DK3374359T3 (da) Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK2988743T3 (da) Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3302063T3 (da) Fremgangsmåde til stimulering af frø
DK3393468T3 (da) Fremgangsmåder til behandling af en immundefektsygdom
DK3465085T3 (da) Bærerstøttet sporing
DK3353177T3 (da) Tricykliske heterocykler til behandling af cancer
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
ITUA20163081A1 (it) Tutore gamba-piede alto di scarico.
DK3303616T3 (da) Fremgangsmåder til prognose af prostatakræft
DK3105220T3 (da) Fremgangsmåde til fremstilling af pyrimidinsulfamidderivater
DE102016117105A8 (de) Antenneneinrichtung
ITUA20164548A1 (it) Skateboard perfezionato.
DK3232555T3 (da) Fremgangsmåde, indretning og system til fordelt styring af undermodul
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
ES1150114Y (es) Abarcón.